Maximus, Inc. (MMS) Expected to Announce Earnings of $0.76 Per Share
Brokerages predict that Maximus, Inc. (NYSE:MMS) will announce earnings per share of $0.76 for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Maximus’ earnings, with the lowest EPS estimate coming in at $0.75 and the highest estimate coming in at $0.78. Maximus posted earnings of $0.77 per share in the same quarter last year, which indicates a negative year over year growth rate of 1.3%. The firm is expected to issue its next earnings report on Thursday, November 9th.
On average, analysts expect that Maximus will report full-year earnings of $3.13 per share for the current year, with EPS estimates ranging from $3.12 to $3.14. For the next year, analysts forecast that the company will post earnings of $3.22 per share, with EPS estimates ranging from $3.15 to $3.30. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Maximus.
Maximus (NYSE:MMS) last released its earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.03. Maximus had a return on equity of 25.08% and a net margin of 8.43%. The firm had revenue of $600.40 million for the quarter, compared to analysts’ expectations of $614.12 million. During the same quarter in the previous year, the business posted $0.79 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis.
MMS has been the topic of several recent analyst reports. Zacks Investment Research cut Maximus from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. KeyCorp reiterated a “sector weight” rating on shares of Maximus in a research report on Thursday, May 25th. Maxim Group lowered Maximus from a “buy” rating to a “hold” rating and set a $66.00 price objective on the stock. in a research report on Thursday, May 4th. They noted that the move was a valuation call. ValuEngine lowered Maximus from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, Jefferies Group LLC lowered Maximus from a “buy” rating to a “hold” rating and increased their price objective for the company from $63.00 to $64.00 in a research report on Friday, May 5th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $62.17.
In related news, General Counsel David Francis sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $63.14, for a total transaction of $63,140.00. Following the transaction, the general counsel now directly owns 18,716 shares in the company, valued at approximately $1,181,728.24. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Richard A. Montoni sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $62.81, for a total value of $1,884,300.00. Following the transaction, the chief executive officer now owns 584,114 shares in the company, valued at $36,688,200.34. The disclosure for this sale can be found here. Insiders have sold a total of 109,636 shares of company stock worth $6,874,122 over the last quarter. Corporate insiders own 3.10% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. raised its position in Maximus by 3.9% in the second quarter. Principal Financial Group Inc. now owns 278,352 shares of the health services provider’s stock valued at $17,433,000 after buying an additional 10,418 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in Maximus by 44.5% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 9,125 shares of the health services provider’s stock valued at $572,000 after buying an additional 2,812 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Maximus by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock valued at $148,000 after buying an additional 220 shares during the last quarter. Pacer Advisors Inc. raised its position in Maximus by 11.8% in the second quarter. Pacer Advisors Inc. now owns 8,688 shares of the health services provider’s stock valued at $544,000 after buying an additional 920 shares during the last quarter. Finally, Airain ltd raised its position in Maximus by 49.8% in the second quarter. Airain ltd now owns 8,214 shares of the health services provider’s stock valued at $514,000 after buying an additional 2,732 shares during the last quarter. Institutional investors and hedge funds own 97.89% of the company’s stock.
Maximus (MMS) traded down 0.98% on Tuesday, reaching $60.90. The company’s stock had a trading volume of 407,776 shares. The firm has a market cap of $3.95 billion, a PE ratio of 19.97 and a beta of 1.39. Maximus has a 52-week low of $43.69 and a 52-week high of $64.97. The stock’s 50 day moving average price is $61.60 and its 200 day moving average price is $60.73.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 31st. Stockholders of record on Tuesday, August 15th will be given a dividend of $0.045 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $0.18 annualized dividend and a dividend yield of 0.30%. Maximus’s dividend payout ratio (DPR) is presently 5.73%.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.